<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313079</url>
  </required_header>
  <id_info>
    <org_study_id>HEMALL0003</org_study_id>
    <secondary_id>96613</secondary_id>
    <nct_id>NCT00313079</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Adult Patients With Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steven E. Coutre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal&#xD;
      antibody that kills B cell acute lymphoblastic leukemia. Trial will study safety,&#xD;
      pharmacokinetics, and anti tumor activity of the antibody given as a single agent and with&#xD;
      vincristine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In this phase I study the endpoint is the determination of the maximum tolerable dose without toxicity.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>A decrease in leukemic blasts. The study will be terminated if unacceptable doseSecondary endpoints are a decrease in leukemic blasts. The study will be terminated if unacceptable dose limiting toxicity is found. This is a phase I trial to study safety.</measure>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Leukemia, Lymphocytic</condition>
  <condition>Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAb 216</intervention_name>
    <description>Dosage: 1.25mg/kg intravenous with dose escalation</description>
    <other_name>Monoclonal Antibody 216</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Dosage: 1.5mg/m2 intravenous weekly X 4</description>
    <other_name>Oncovin</other_name>
    <other_name>leurocristine</other_name>
    <other_name>VCR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        3.1.1 Age Patients must be &gt;= 18 years old at the time of study entry.&#xD;
&#xD;
        3.1.2 Diagnosis&#xD;
&#xD;
        3.1.2.1 Histologic Verification Patients must have had histologic verification of B-lineage&#xD;
        ALL with bone marrow relapse or refractory disease that is unresponsive to traditional&#xD;
        chemotherapy.&#xD;
&#xD;
        3.1.2.2 For patients WITHOUT prior allogeneic BMT:&#xD;
&#xD;
          1. Second or subsequent bone marrow relapse&#xD;
&#xD;
          2. Primary refractory marrow disease&#xD;
&#xD;
          3. M3 marrow (&gt;25% blasts) or &gt;25% leukemic blasts in peripheral blood&#xD;
&#xD;
        3.1.2.3 For patients WITH prior allogeneic BMT:&#xD;
&#xD;
          1. First or subsequent bone marrow relapse post-BMT&#xD;
&#xD;
          2. M3 marrow or M2 (&gt;5 % and &lt;25% blasts) if cytogenetic or VNTR confirmation&#xD;
&#xD;
        3.1.3 Confirmation of antibody reactivity 3.1.3.1 Patient's leukemic blasts (peripheral&#xD;
        blood or marrow) must be documented to bind mAb 216 in vitro (Teng lab) 3.1.3.2 Patient's&#xD;
        RBC documented to NOT express fetal &quot;i&quot; antigen and RBC shown to NOT bind mAb 216 in vitro&#xD;
        (Teng lab)&#xD;
&#xD;
        3.1.4 Patient Must Not Be Eligible For Therapies of Higher Priority&#xD;
&#xD;
        3.1.5 Performance Level (See Appendix I) Karnofsky &gt;= 50%&#xD;
&#xD;
        3.1.6 Life Expectancy Must be at least 8 weeks.&#xD;
&#xD;
        3.1.7 Prior Therapy Patients must have fully recovered from the acute toxic effects of all&#xD;
        prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.&#xD;
&#xD;
          1. Myelosuppressive chemotherapy: Must not have received within one week of entry onto&#xD;
             this study.&#xD;
&#xD;
          2. Biologic, including monoclonal antibodies: At least 2 weeks since the completion of&#xD;
             therapy with a biologic agent including monoclonal antibodies.&#xD;
&#xD;
          3. Hydroxyurea can be used up to 72 hours before study entry&#xD;
&#xD;
        3.1.8 Organ Function Requirements&#xD;
&#xD;
        3.1.8.1 Bone Marrow Function: 3.1.8.1.1 No hematologic criteria for WBC, Hgb or platelets&#xD;
        3.1.8.1.2 Patients with thrombocytopenia should be responsive to platelet transfusions and&#xD;
        must not have uncontrolled bleeding.&#xD;
&#xD;
        3.1.8.2 Adequate Renal Function Defined As:&#xD;
&#xD;
        - A serum creatinine that is less than or equal to 2 x normal for age&#xD;
&#xD;
        3.1.8.3 Adequate Liver Function Defined As:&#xD;
&#xD;
          -  Total bilirubin &lt;= 2 x upper limit of normal (ULN) for age, and&#xD;
&#xD;
          -  SGPT (ALT) &lt;= 5 x upper limit of normal (ULN) for age&#xD;
&#xD;
        3.1.8.4 Adequate Cardiac Function Defined As:&#xD;
&#xD;
          -  Shortening fraction of &gt;= 27% by echocardiogram, or&#xD;
&#xD;
          -  Ejection fraction of &gt;= 50% by gated radionuclide study.&#xD;
&#xD;
        3.1.9 Regulatory&#xD;
&#xD;
        3.1.9.1 All patients must sign a written informed consent. 3.1.9.2 All institutional (IRB)&#xD;
        and FDA requirements for human studies must be met.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        3.2.1 CNS 3 or refractory CNS leukemia&#xD;
&#xD;
        3.2.2 Isolated extramedullary relapse&#xD;
&#xD;
        3.2.3 Uncontrolled infection&#xD;
&#xD;
        3.2.4 Lack of mAb 216 binding to patient's leukemic blasts in vitro&#xD;
&#xD;
        3.2.5 Binding of mAb 216 to the &quot;i&quot; antigen on patient's erythrocytes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelson N Teng</last_name>
    <role>Sub-Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Liedtke M, Twist CJ, Medeiros BC, Gotlib JR, Berube C, Bieber MM, Bhat NM, Teng NN, Coutre SE. Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Haematologica. 2012 Jan;97(1):30-7. doi: 10.3324/haematol.2011.045997. Epub 2011 Oct 11.</citation>
    <PMID>21993685</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>April 7, 2006</study_first_submitted>
  <study_first_submitted_qc>April 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2006</study_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Steven E. Coutre</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

